|
|
|
|
|
|
|
M Tue W Th F |
|
14 July, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
One piece of news that caught my eye from the team today: Biossil, a startup backed by OpenAI and Founders Fund, bought a Phase 3 antibiotic program from Summit. The startup also bought some cancer drugs — it's always intriguing to see what OpenAI-backed companies are getting up to in biopharma. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Bayer
|
After setting the industry ablaze last month, a bipartisan bill aimed at restricting US biotech companies from striking deals with Chinese counterparts is in limbo... | |
|
|
|
|
|
|
by Drew Armstrong
|
Late last year, I found myself talking a lot about what it would take for biotech’s budding rally to become a full one. We had... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
AstraZeneca is set to pay Dizal Pharmaceutical, which it part-owns, $600 million upfront for worldwide development and sales rights to the lung cancer drug Zegfrovy... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public
offeringcame after it... | |
|
|
|
 |
|
AAIC in London (Ryan Cross for Endpoints News) |
|
|
|
by Ryan Cross
|
LONDON— Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Chai Discovery, one of the hottest startups in the AI-generated drug discovery landscape, has corralled $400 million in a Series C that triples its paper... | |
|
|
|
|
|
